THE COMPARATIVE STUDY BETWEEN OBETICHOLIC ACID AND URSODEOXYCHOLIC IN NONALCOHOLIC STEATOHEPATITIS (NASH) MANAGEMENT
Md. Kutub Uddin Mollick*, Sukumar Saha, Utpal Kumar Chanda, Gazi Salahuddin and Mamun Al Mahtab
Objective: In this study our main goal is to evaluate the effectiveness of obeticholic acid and ursodeoxycholic in non alcoholic steatohepatitis management. Method: This cross sectional study was carried out at Tertairy Medical hospital January 2019 to January 2020. Where a total of 60 patients with a clinical and laboratory diagnosis of NASH, on a stable dose of UDCA for at least 6 months prior to screening, were randomly assigned (1:1:1) to one of three treatment groups for 85 days (3 months): OCA 10 mg, OCA 25 mg, OCA 50 mg or a matching placebo administered once daily. Results: During the study, out of 60 patients (40%) were 30 or below 30 years old, (26.6%) 31-40 years and (20%) 41-50 years and majority were male, 80%. C-reactive protein (CRP) showed significant reductions from baseline at the end of the study with OCA treatment. In OCA 25 mg group Improvement of fibrosis was 24% without worsening of NASH and 12% resolution cases of NASH with no worsening of fibrosis. Conclusion: Daily doses of OCA, ranging from 10 to 25 mg, significantly reduced levels of ALP, lipid profile, and alanine aminotransferase, compared to placebo, in patients with NASH who had inadequate responses to UDCA. Further study is needed for better outcome.
Keywords: obeticholic acid (0CA), ursodeoxycholic, nonalcoholic steatohepatitis (NASH).
[Full Text Article]